Related Experiment Video
Updated: Jun 14, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Dual-target CAR-T cell therapy: latest updates from the 2025 ASH annual meeting
Shi Feng1, Ran Kong1, Li Xiao2
1Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No.324, Jingwu Road, Jinan, 250021, Shandong, China.
Dual-target CAR-T cell therapy shows promise for overcoming limitations of single-target approaches. Advancements in engineering and preclinical data suggest improved disease control in various cancers and autoimmune diseases.
Area of Science:
- Immunotherapy
- Cellular Therapy
- Oncology
Background:
- Single-target CAR-T therapy faces challenges like antigen heterogeneity and escape.
- Dual-target CAR-T cell therapy is being developed to overcome these limitations.
More Related Videos
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers